Catalyst
Slingshot members are tracking this event:
Further Analysis of Rigel's (RIGL) Cohort 1 Phase 2 Data Evaluating Fostamatinib in IgA Nephropathy to be Presented in 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| RIGL |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 15, 2017
Occurred Source:
http://ir.rigel.com/phoenix.zhtml?c=120936&p=irol-newsArticle&ID=2268893
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Further Analysis, Preliminary Data, Cohort 1, Fostamatinib, Iga Nephropathy
